Evidence map›Paper›PMID 41466749›Full record

ArticleJHEP reports : innovation in hepatology2025

Corrigendum to "Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study" [JHEP Reports 2025 7(10) 101516].

Edward Gane, Ewa Janczewska, Tetsuo Takehara, Wan-Long Chuang, Cheng-Yuan Peng, Maria Hlebowicz, Yasuhiro Asahina, Ting-Tsung Chang, Ronald Kalmeijer, John Jezorwski and 8 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Edward GaneUniversity of Auckland, Auckland, New Zealand.
Ewa JanczewskaID Clinic, Myslowice, Poland.
Tetsuo TakeharaOsaka University Graduate School of Medicine, Osaka, Japan.
Wan-Long ChuangKaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Cheng-Yuan PengDepartment of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Maria HlebowiczDepartment of Family Medicine and Infectious Diseases, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
Yasuhiro AsahinaDepartment of Gastroenterology and Hepatology, Institute of Science Tokyo, Bunkyo-Ku, Japan.
Ting-Tsung ChangDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ronald KalmeijerJohnson & Johnson, Titusville, NJ, USA.
John JezorwskiJohnson & Johnson, Titusville, NJ, USA.
Gloria KimIQVIA, Durham, NC, USA.
Zacharias AnastasiouJanssen-Cilag Pharmaceutical, Pefki, Greece.
Thomas N KakudaJohnson & Johnson, Brisbane, CA, USA.
Thierry VerbinnenJanssen Pharmaceutica NV, Beerse, Belgium.
Nonko PehlivanovJohnson & Johnson, Titusville, NJ, USA.
Adam BakalaJanssen Pharmaceutica NV, Beerse, Belgium.
Oliver LenzJanssen Pharmaceutica NV, Beerse, Belgium.
Michael BiermerJanssen Pharmaceutica NV, Beerse, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.1016/j.jhepr.2025.101516.].

Identifiers

PMID41466749
PMCPMC12744829

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.